Patients Previously Treated with an HCV Regimen Containing:
VOSEVI Duration
* In clinical trials, prior NS5A inhibitor experience included daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir. * In clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon alfa/ribavirin, ribavirin, HCV NS3/4A protease inhibitor (boceprevir, simeprevir, or telaprevir).
1, 2, 3, 4, 5, or 6
An NS5A inhibitor *
12 weeks
1a or 3
Sofosbuvir without an NS5A inhibitor †
12 weeks
* For patients with renal impairment including end stage renal disease on dialysis, follow the dosage recommendations in the table above. * VOSEVI is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
Other resources
Learn More
Other resources brands publish to help support patients.
people also ask
Vosevi FAQs
How is the dosage of Vosevi?Vosevi is available in 1 dosages, including 400-100-100 mg Tab
What does Vosevi treat?Vosevi treats Chronic Hepatitis C
What is Vosevi made of?Vosevi contains sofosbuvir / velpatasvir / voxilaprevir which is a Hepatitis C Virus NS3/4A Protease Inhibitor
How Is Vosevi Administered?Vosevi is administered as a Oral Pill
What Are The Vosevi Mechanism Of Action?Vosevi mechanism of action is Breast Cancer Resistance Protein Inhibitors, HCV NS3/4A Protease Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Organic Anion Transporting Polypeptide 1B3 Inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-Glycoprotein Inhibitors or RNA Replicase Inhibitors
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available